• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • Patient Education
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Covance Ups Guidance as Early- and Late-Stage Revenues Improve in Q2

Covance Ups Guidance as Early- and Late-Stage Revenues Improve in Q2

July 29, 2009
CenterWatch Staff

Covance reported an increase in both early- and late-stage drug development revenues for the second quarter of 2009 compared with the first quarter, but early-stage revenues remain significantly lower than the same period last year.

Early-stage net revenues were $199.8 million in the second quarter—a $7-million increase over the first quarter—but a drop from $213.1 million in Q2 2008.  The contract research organization (CRO) attributed the decrease in revenues to a lower demand in toxicology in 2009. The early-stage segment’s operating income declined 50% from the same period last year to $27.1 million.

Late-stage development revenues and income were up in the second quarter, compared with both the first quarter 2009 and Q2 of last year. Late-stage revenues grew 19% to $266.3 million, compared to $223.8 million in the second quarter 2008, and operating income increased 52.4% to $65.5 million compared to $43 million prior year.

Covance’s overall revenues climbed 6.7% from the same period last year. Revenues for the quarter were $489.2 million, compared with $461.8 million in Q2 2008. Profits for the CRO were down 15.5% to $43 million from $50.9 million in 2008. Earnings per share also fell 16% to $0.67 per share.

The company expects sequential growth to continue in the third quarter, said Covance chairman and CEO Joe Herring.

“We are upwardly adjusting our 2009 revenue growth target to the mid- to upper-single digits and our earnings per share target to a range of $2.60 to $2.80 per share (excluding gains on the sales of our centralized ECG and IVRS service lines and using June 30 exchange rates), versus our previous targets of single-digit revenue growth and earnings of $2.50 to $2.70 per share," Herring said in a company statement.  

Upcoming Events

  • 15Apr

    Five Telltale Signs You’re Ready for an Electronic TMF System

  • 26Apr

    MAGI's Clinical Research vConference — Spring 2021

  • 06May

    The World of Post-COVID-19 Clinical Trials: How to Prepare for What’s Coming Next

Featured Products

  • Regenerative Medicine – Steps to Accelerate Development : PDF

    Regenerative Medicine: Steps to Accelerate Development

  • Clinical Trial Agreements — A Guide to Key Words and Phrases : PDF

    Clinical Trial Agreements: A Guide to Key Words and Phrases

Featured Stories

  • Clinical-Trial-Brainstorming

    FDA, Industry Tackle Problem of Including Older Adults in Trials

  • ClinicalTrialNetwork-360x240.png

    National Community-Based Research Network Would Improve Reach of Trials

  • Bottleneck-360x240.png

    Sites Face Trials Bottleneck After Pandemic, But Also Opportunities

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Genetic Research and IBC Oversight Requirements

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2021. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing